title: A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.
authors: Astellas Global Medical Affairs, Northbrook, IL; Department of Urology, Loyola University School of Medicine, Maywood, IL. Electronic address: gabriel.haas@astellas.com.
authors: Gabriel P
authors: GP
authors: Haas
authors: Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
authors: Howard I
authors: HI
authors: Scher
mesh_terms: D019985:Benchmarking / Q000379:methods*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D055808:Drug Discovery; D006801:Humans; D008495:Medical Oncology; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D014408:Biomarkers, Tumor